目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T81962 | Monocarboxylate transporter | ||
Lactate transporter 1 (compound 1) 作为一种活性乳酸运输蛋白,主要在活细胞内发挥作用。在Hela、CAL27、MCF7和MCF10A细胞系中,Lactate transporter 1 均显示出了明显的毒性,其半抑制浓度(IC50)值依次为3.36、3.27、5.58和7.66 μM。此外,在HeLa细胞中,Lactate transporter 1 与Cisplatin表现出了协同抑制的作用。 | |||
T81689 | |||
Neohelmanthicin A(compound 3A)是具抗肿瘤活性的苯丙素类化合物。该化合物对EL4白血病细胞系、S180乳腺癌细胞系和MCF7乳腺癌细胞系表现出显著的抑制作用,其IC50s分别为0.13 μM, 7 μM和23 μM。 | |||
T70345 | |||
JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly. JAS239 attenuated choline phosphorylation and viability in a panel of human breast cancer cell lines. Antibody blockade prevented cellular retention of JAS239 indicating direct interaction with ChoKα independent of the choline transporters and catabolic choline pathways. In mice bearing orthotopic MCF7 breast xenografts, optical imaging with JAS239 distinguished tumors overexpressing ChoKα from their empty vector counterparts and delineated tumor margins. | |||
T61229 | |||
VEGFR-2/DHFR-IN-2 (compound 5b) is a dual inhibitor targeting VEGFR-2 and DHFR, with respective IC50 values of 0.623 μM and 9.085 μM. It demonstrates potent cytotoxicity against C26, HepG2, and MCF7 cancer cell lines, with IC50 values ranging from 3.59 μM to 8.38 μM. VEGFR-2/DHFR-IN-2 holds promise for cancer research [1]. | |||
T72742 | |||
(-)-Pinocembrin 对 H37Ra 结核分枝杆菌展示了抗菌活性,无论是休眠还是活跃期,其 IC50 值分别为1.11 mg/mL 和 1.21 mg/mL。作为一种抗增殖剂,(-)-Pinocembrin 对于 THP-1、A549、Panc-1、HeLa 和 MCF7 细胞系,IC50 值范围为 1.88 至 11.00 mg/mL。 | |||
T82492 | EGFR | ||
EGFR/HER2/DHFR-IN-3(compound 4c)是一种针对EGFR和HER2的高效双重抑制剂,其IC50分别为0.138 μM和0.092 μM。该化合物同时对DHFR具有抑制作用,IC50为0.193 M。在生物活性方面,EGFR/HER2/DHFR-IN-3能够导致MCF7乳腺癌细胞周期在S期发生阻滞,并进而诱导细胞凋亡。 | |||
T78773 | |||
Tubulin inhibitor 38(化合物14)是一款强效的四唑基微管蛋白抑制剂,能够显著抑制细胞增殖。以100 nM浓度作用24小时后,该抑制剂能够引起有丝分裂停滞,特别是在G2/M期细胞周期阶段,进而诱导细胞凋亡。在HeLa、MCF7和U87 MG细胞系中,Tubulin inhibitor 38展现了较高的细胞毒性及选择性。 | |||
T82493 | EGFR | ||
EGFR/HER2/DHFR-IN-2 (Compound 4b) 是针对EGFR、HER2和DHFR的三重抑制剂,IC50分别为0.248、0.156、0.138 μM。该化合物对包括Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7在内的多种癌细胞系展现出显著的抗癌活性(IC50分别为9.14、7.33、14.18、24.87、20.07、6.16 μM),并能有效减缓乳腺癌肿瘤的生长。 | |||
T69403 | |||
AZD-3409 is a potent prenyl transferase inhibitor. AZD-3409 showed higher potency than lonafarnib. The mean IC(50) for cytotoxicity of AZD3409 was 510 in MEF cells, 10,600 in A549 cells and 6,170 in MCF7 cells, respectively. In these cells, the IC(50) for FTase activity of AZD3409 ranged from 3.0 to 14.2 nM and of lonafarnib from 0.26 to 31.3 nM. AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. Both inhibition of farnesylation and geranylgeranylation could not be correlated to the antiproliferative activity of the drug. AZD3409 might be active in gefitinib-resistant breast carcinoma. | |||
T61489 | |||
VEGFR-2/DHFR-IN-1 (compound 8b) 是 VEGFR-2和DHFR 的抑制剂,其IC50值分别为 0.384 和 7.881 μM。VEGFR-2/DHFR-IN-1 对大肠埃希菌,粪链球菌,肠沙门氏菌,金黄色酿脓葡萄球菌,MSSA 和MRSA 显示了良好的抗菌活性,MIC 值分别为 16,16,16,8 和 16 μg/mL。VEGFR-2/DHFR-IN-1 对 C26,HepG2 和 CF7 癌细胞系具有良好的细胞毒性,IC50值为 2.97-7.12 μM。VEGFR-2/DHFR-IN-1 可用于癌症的研究。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-00785 | ANXA2 Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
ANXA2, highly expressed in invasive breast cancer cells, is closely related with poor prognosis, and acts as a molecular switch to EGFR activation. ANXA2 expression is inversely correlated with cell sensitivity to gefitinib. Knockdown of ANXA2 expression in MDA-MB-231 cells increased the gefitinib induced cell death. When ANXA2 was overexpressed in MCF7 cells, the gefitinib induced cell death was decreased. Furthermore, the phosphorylation of ANXA2 at Tyr23 is negatively correlated with the sensitivity of TNBC to gefitinib.
|
|||||
TMPK-00784 | ANXA2 Protein, Human, Recombinant (His) | Human | E. coli | ||
ANXA2, highly expressed in invasive breast cancer cells, is closely related with poor prognosis, and acts as a molecular switch to EGFR activation. ANXA2 expression is inversely correlated with cell sensitivity to gefitinib. Knockdown of ANXA2 expression in MDA-MB-231 cells increased the gefitinib induced cell death. When ANXA2 was overexpressed in MCF7 cells, the gefitinib induced cell death was decreased. Furthermore, the phosphorylation of ANXA2 at Tyr23 is negatively correlated with the sensitivity of TNBC to gefitinib.
|